




# MEDICINAL PRODUCTS 2023



MyMD Pharmaceuticals Inc.  
Rank 35 of 48





# MEDICINAL PRODUCTS 2023



MyMD Pharmaceuticals Inc.  
Rank 35 of 48

The relative strengths and weaknesses of MyMD Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MyMD Pharmaceuticals Inc. compared to the market average is the variable Assets, Non-Current, increasing the Economic Capital Ratio by 202% points. The greatest weakness of MyMD Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is -27%, being 22% points below the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	5,402
Assets, Non-Current	12,138
General and Administrative Expense	5,520
Goodwill	10,499
Liabilities, Current	2,769
Liabilities, Non-Current	76
Other Assets	-10,499
Other Compr. Net Income	0
Other Expenses	695
Other Liabilities	0
Other Net Income	85
Other Revenues	0
Property, Plant and Equipment, Net	0
Research and Development	9,067

Output Variable	Value in 1000 USD
Liabilities	2,845
Assets	17,540
Expenses	15,283
Revenues	0
Stockholders Equity	14,695
Net Income	-15,197
Comprehensive Net Income	-15,197
Economic Capital Ratio	-27%